Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
186 hedge funds and large institutions have $893M invested in Revance Therapeutics, Inc. in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 87 increasing their positions, 51 reducing their positions, and 43 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 51
28% more call options, than puts
Call options by funds: $15.9M | Put options by funds: $12.5M
13% less funds holding
Funds holding: 215 → 186 (-29)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
57% less capital invested
Capital invested by funds: $2.07B → $893M (-$1.18B)
60% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$45.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$34.1M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$30.8M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$22.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$61.1M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$48.2M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$31.6M |
| 4 |
Two Sigma Advisers
New York
|
-$28.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$23.6M |
RVNC Hedge Fund Activity: Q3 2023 in Review
186 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2023, worth a combined $893M — down 57% from $2.07B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of RVNC and 17 opened new positions — a net loss of 26 holders — while 51 trimmed existing stakes and 87 added.
The largest buyer was Capital World Investors, adding an estimated $45.9M. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $61.1M.
- 186 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2023, down from 215 in Q2 2023.
- Funds reported $893M of Revance Therapeutics, Inc. stock for Q3 2023, down 57% quarter-over-quarter.
- 17 funds opened new Revance Therapeutics, Inc. positions in Q3 2023 and 43 closed out, a net change of -26 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2023 was Capital World Investors, an estimated $45.9M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2023 was Thrivent Financial for Lutherans, an estimated $61.1M sold.
Based on aggregated 13F filings for Q3 2023.